Free tool
FAERS Monitor: Bepreve
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022288 or its brand name (Bepreve, Bepotastine Besilate). Reports on generic versions are filed under their own applications.
Reports
644
Serious
361
56% of reports
Hospitalization
174
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective45
- headache36
- nausea33
- eye irritation32
- fatigue32
- pain29
- diarrhoea28
- pruritus27
- treatment failure26
- dyspnoea25
- off label use25
- asthma24
- arthralgia23
- malaise23
- dysgeusia22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 22 |
| 2011 | 46 |
| 2012 | 11 |
| 2013 | 18 |
| 2014 | 17 |
| 2015 | 45 |
| 2016 | 47 |
| 2017 | 73 |
| 2018 | 62 |
| 2019 | 76 |
| 2020 | 65 |
| 2021 | 54 |
| 2022 | 22 |
| 2023 | 25 |
| 2024 | 22 |
| 2025 | 23 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,515 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye irritationSignal | 32 | 18.2 | 13.0 | 503 |
| treatment failureSignal | 26 | 10.3 | 7.0 | 209 |
| dysgeusiaSignal | 22 | 9.7 | 6.4 | 163 |
| asthmaSignal | 24 | 6.9 | 4.7 | 117 |
| pruritusSignal | 27 | 2.3 | 1.6 | 19 |
| headache | 36 | 1.9 | 1.4 | 14 |
| arthralgia | 23 | 1.8 | 1.2 | 8 |
| malaise | 23 | 1.7 | 1.1 | 6 |
| pain | 29 | 1.5 | 1.1 | 5 |
| dyspnoea | 25 | 1.4 | 1.0 | 3 |
| diarrhoea | 28 | 1.4 | 1.0 | 3 |
| nausea | 33 | 1.4 | 1.0 | 3 |
| fatigue | 32 | 1.3 | 1.0 | 3 |
| drug ineffective | 45 | 1.1 | 0.8 | 0 |
| off label use | 25 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.